ZJYLJin Medical International Ltd

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Erqi Wang

Location

N/A, China

Exchange

Nasdaq

Website

https://www.zhjmedical.com/

Summary

The China-based VIE, Changzhou Zhongjin, and its subsidiaries, design and manufacture wheelchairs and living aids products for people with disabilities, the elderly, and people recovering from injury.

Company Info

CEO

Erqi Wang

Location

N/A, China

Exchange

Nasdaq

Website

https://www.zhjmedical.com/

Summary

The China-based VIE, Changzhou Zhongjin, and its subsidiaries, design and manufacture wheelchairs and living aids products for people with disabilities, the elderly, and people recovering from injury.

AI Insights for ZJYL
5 min read

Quick Summary

Jin Medical International Ltd. is a China-based medical equipment company that designs, manufactures, and sells wheelchairs and living-aid products. The company operates through Chinese operating entities and is legally structured as a Cayman Islands holding company with business activities centered in Changzhou, Jiangsu Province, China. Its products are aimed at people with disabilities, elderly users, and patients recovering from injuries or mobility-limiting conditions. The company sells mainly through distributors in China and overseas, with important end markets including China and Japan. Its business focuses on rehabilitation mobility products, and recent announcements show that it is trying to expand further into electric wheelchairs and mobility scooters.

Strengths

•

Jin Medical has a focused niche in rehabilitation mobility products, especially wheelchairs and living aids for elderly and disabled users.

•

The company has an established operating history dating back to 2006 and has manufacturing facilities in Jiangsu Province, which may support cost-efficient production.

•

It works with more than 40 distributors in China and more than 20 overseas distributors, giving it access to both domestic and international customers.

•

The company reports ownership of 106 patents and is registering 22 additional patents, which may support product development and differentiation.

•

Its low valuation metrics, profitability, and positive net income may attract speculative investors if the company can prove revenue growth and improve investor confidence.

Key Risks

•

Jin Medical faces significant risks from intense competition, low margins, product quality requirements, regulatory compliance, and dependence on distributors.

•

As a China-based issuer listed in the United States, it may be affected by U.S.-China regulatory tensions, audit oversight rules, investor skepticism, and governance concerns.

•

The reverse split may help with Nasdaq price compliance, but it does not by itself improve business fundamentals, and post-split shares can remain volatile.

•

The company’s new product sales expectations are forward-looking and may not materialize if demand, production, pricing, or distribution execution disappoints.

What to Watch

During the most recent reported period, Jin Medical reported operating revenue of about $41.37 million, gross profit of about $6.04 million, operating income of about $0.61 million, and net income of about $2.57 million.
The company also reported basic and diluted EPS of $0.01, which indicates profitability but limited per-share earnings before the announced share combination.
A major corporate event was the board approval of a 1-for-20 share combination after shareholder authorization at an extraordinary general meeting on January 30, 2026.
The company also reclassified its share capital into Class A and Class B ordinary shares, with trading expected to continue on Nasdaq under the ticker ZJYL on a split-adjusted basis.
In addition, Jin Medical announced two new electric mobility products developed with Nanjing Tech University, including an ultralight electric wheelchair and an elderly-focused electric mobility scooter.

Price Drivers

•

ZJYL’s stock price is likely driven by a combination of micro-cap trading dynamics, Nasdaq listing compliance concerns, company earnings, liquidity, and investor reaction to corporate actions.

•

The company has a very small market capitalization of about $14.95 million and a very high beta of 7.33, which suggests that the stock can be extremely volatile relative to the broader market.

•

The announced 1-for-20 share combination is a major price driver because it is intended to support Nasdaq continued listing compliance, but reverse splits often create uncertainty among investors.

•

Fundamental valuation metrics appear low, including a price-to-earnings ratio around 8.1, EV-to-revenue around 0.10, and price-to-book around 0.50, but micro-cap China-listed companies can trade at discounts due to governance, liquidity, and regulatory concerns.

•

Product news, especially the launch of electric wheelchairs and mobility scooters, may also affect sentiment if investors believe these products can increase revenue and profitability.

Recent News

•

Jin Medical recently announced that its board approved a 1-for-20 share combination following shareholder authorization at an extraordinary general meeting on January 30, 2026.

•

The combination is scheduled to take effect on March 16, 2026, and the company’s Class A shares are expected to continue trading on the Nasdaq Capital Market under the ticker ZJYL on a split-adjusted basis.

•

The company also reclassified its share capital into Class A and Class B ordinary shares, with outstanding Class A shares decreasing from 136,547,100 to 6,827,355 and Class B shares decreasing from 20,000,000 to 1,000,000.

•

Separately, the company announced an ultralight electric wheelchair and an electric mobility scooter developed with Nanjing Tech University.

•

Management described these launches as an important step in expanding the electric wheelchair and mobility scooter business, which currently represents a small portion of total sales.

Market Trends

•

The rehabilitation and mobility equipment market is supported by aging populations, rising chronic disease prevalence, greater awareness of disability access, and demand for home-based care.

•

In China and Japan, elderly-care needs are increasing, which may support demand for wheelchairs, scooters, and living-aid products.

•

Consumers are also increasingly interested in lighter, foldable, battery-powered, and technology-enhanced mobility products that improve independence and convenience.

•

At the same time, the market is competitive, and buyers often compare products based on price, reliability, safety certifications, comfort, and after-sales service.

•

Broader market conditions, including investor caution toward small-cap Chinese issuers and volatile Nasdaq micro-cap trading, can strongly affect ZJYL’s stock even when industry demand trends are favorable.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on ZJYL

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show